DEF 14A: OpGen Seeks Stockholder Approval for Share Issuance, Change of Control, and Reverse Stock Split

OpGen is convening a special meeting of stockholders to vote on proposals including a share issuance to David Lazar, a reverse stock split, and adjournment if necessary.

Summary

• OpGen, Inc. is holding a Special Meeting of Stockholders on May 9, 2024, to vote on three proposals.
• Proposal 1 involves the approval of a share issuance to David Lazar, which would result in a change of control under Nasdaq rules, and an amendment to the Certificate of Designations to remove ownership limitations.
• If approved, Mr. Lazar could own approximately 85% of OpGen's Common Stock.
• Proposal 2 concerns the approval of an amendment to the company's Certificate of Incorporation to effect a reverse stock split at a ratio between two-to-one and ten-to-one, with the specific ratio and timing determined by the Board of Directors.
• Proposal 3 is to approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are insufficient votes to approve the other proposals.
• The Board of Directors recommends voting in favor of all three proposals.

Sentiment

Score: 4

Explanation: The document conveys a mixed sentiment. While the investment from David Lazar provides immediate financial relief, the potential change of control and reverse stock split raise concerns about the company's future direction and stock performance. The risk of bankruptcy if the proposals are not approved further dampens the outlook.

Positives

• The $3.0 million investment from David Lazar is expected to improve OpGen's financial condition and address its liquidity needs.
• The funding from Mr. Lazar would allow OpGen to explore strategic alternatives to maximize stockholder value.
• The Board believes the reverse stock split could help the company regain compliance with Nasdaq's minimum bid price requirement and make the stock more attractive to a broader range of investors.

Negatives

• Approval of the share issuance would result in a change of control, with David Lazar becoming the majority stockholder.
• The reverse stock split may not result in a permanent increase in the market price of the common stock.
• The reverse stock split could decrease the liquidity of the common stock and increase the number of stockholders who own odd lots.

Risks

• If the share issuance is not approved, the company may need to seek bankruptcy protection.
• There is no guarantee that the reverse stock split will increase the stock price or maintain Nasdaq listing compliance.
• David Lazar's significant ownership percentage could allow him to exert significant influence over the company's decisions.
• The Board acknowledges potential risks associated with Mr. Lazar's significant ownership percentage following the Closing, including their right to designate a majority of directors to the Board, which will enable them to affect the outcome of, or exert significant influence over, all matters requiring Board or stockholder approval, including the election and removal of directors and any change in control, and could have the effect of delaying or preventing a change in control of the Company or otherwise discouraging or preventing a potential acquirer from attempting to obtain control of the Company, which, in turn, could have a negative effect on the market price of the Company's Common Stock and could impact the low trading volume and volatility of the Company's Common Stock.

Future Outlook

The company will continue to remain a public company and file reports with the SEC, regardless of whether the proposals are approved, although Nasdaq listing may be affected if the Reverse Stock Split Proposal is not approved.

Management Comments

• The Board determined that the Purchase Agreement and the transactions contemplated thereby, including the issuances of Series E Preferred Shares and the removal of the Ownership Limitations therefrom, are advisable and in the best interests of the Company and its stockholders.

Industry Context

This announcement reflects a company facing financial challenges seeking capital and strategic alternatives, a common scenario in the biotechnology industry, where companies often rely on equity financing to fund operations and research.

Comparison to Industry Standards

• Reverse stock splits are a relatively common strategy for companies facing delisting from major exchanges, with companies like Ocugen and CytoSorbents having recently undertaken similar actions.
• The level of control potentially granted to David Lazar is similar to situations where activist investors or private equity firms take significant stakes in publicly traded companies, such as Carl Icahn's involvement with Herbalife or Elliott Management's investments in various tech companies.
• The potential for bankruptcy if the proposals are not approved is a risk faced by many small-cap biotech companies with limited revenue and high research and development costs, such as Athersys and Heat Biologics.

Stakeholder Impact

• Shareholders face potential dilution and a change in control.
• Employees' job security could be affected by the company's financial situation and strategic direction.
• Customers and suppliers may be impacted by changes in the company's operations and financial stability.
• Creditors' interests are tied to the company's ability to repay its debts.

Next Steps

• Stockholders need to vote on the proposals by the deadline.
• The company will file the amended Certificate of Designations with the Secretary of State of Delaware if Proposal 1 is approved.
• The Board of Directors will determine the specific ratio and timing of the reverse stock split if Proposal 2 is approved.

Key Dates

Keywords

reverse stock split, share issuance, David Lazar, change of control, stockholder approval, Series E Preferred Stock, Nasdaq, OpGen